Drug Insights

Is Darolutamide approved by the FDA?

21 June 2024
3 min read

Yes, Darolutamide is FDA approved. The U.S. Food and Drug Administration (FDA) approved Darolutamide, marketed under the brand name Nubeqa, on July 30, 2019.

What is Darolutamide?

Darolutamide is an antiandrogen medication used primarily to treat nonmetastatic castration-resistant prostate cancer (nmCRPC). It is classified under the drug classes of antiandrogens and hormones/antineoplastics. The medication comes in the form of an oral tablet, typically dosed at 300 mg.

Uses of Darolutamide

Darolutamide is used to treat prostate cancer that has not spread to other parts of the body (nonmetastatic). It is usually prescribed when other treatments, such as surgery or other medications, have not been successful or have stopped working. The primary use of Darolutamide is for men with nonmetastatic castration-resistant prostate cancer (nmCRPC), which means the cancer continues to grow despite low levels of testosterone.

Dosage

The usual dosage of Darolutamide for adults is 600 mg (two 300 mg tablets) taken orally twice a day. The medication should be taken with food. Patients are often also prescribed a gonadotropin-releasing hormone (GnRH) analog or must have had a bilateral orchiectomy (surgical removal of the testicles) to lower testosterone levels in the body.

Side Effects

Common Side Effects:

  • Feeling tired
  • Pain in the arms, hands, legs, or feet
  • Rash
  • Low white blood cell count
  • Abnormal liver function tests

Serious Side Effects:

  • Severe ongoing nausea or diarrhea
  • Painful or difficult urination
  • Blood in urine
  • Severe headache, blurred vision
  • Slow heart rate, weak pulse
  • Signs of a blood clot in the lung (chest pain, sudden cough, wheezing, rapid breathing, coughing up blood)
  • Signs of a lung infection (fever, chills, cough with mucus, chest pain, shortness of breath)

Warnings and Precautions

  • Allergic Reactions: If you experience hives, difficulty breathing, or swelling of the face, lips, tongue, or throat, seek emergency medical help.
  • Pregnancy: Darolutamide is not for use by women, especially those who are pregnant or can become pregnant, as it can harm an unborn baby.
  • Liver or Kidney Disease: Inform your doctor if you have a history of liver or kidney disease.
  • Fertility: It may be harder for men to father a child while using Darolutamide, and effective birth control should be used to prevent pregnancy during treatment and for at least one week after the last dose.

How to Take Darolutamide

  • With Food: Darolutamide should be taken with food to enhance absorption.
  • Do Not Crush or Chew: Swallow the tablet whole without crushing, chewing, or breaking it.
  • Consistency: Take the medication exactly as prescribed by your doctor, typically twice a day.

Drug Interactions

Darolutamide can interact with other medications, which may increase side effects or reduce effectiveness. It is important to inform your healthcare provider about all medications you are taking, including prescription and over-the-counter medicines, vitamins, and herbal products.

Conclusion

Darolutamide (Nubeqa) is an FDA-approved medication used to treat nonmetastatic castration-resistant prostate cancer. Approved on July 30, 2019, it provides a valuable option for men whose prostate cancer has not responded to other treatments. Always consult with a healthcare professional for personalized advice and treatment plans.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Mozart Therapeutics Begins Phase 1 Trial of MTX-101 for Autoimmune Treatment
Latest Hotspot
3 min read
Mozart Therapeutics Begins Phase 1 Trial of MTX-101 for Autoimmune Treatment
21 June 2024
Mozart Therapeutics Administers Initial Dose in Phase 1 Clinical Study of MTX-101 for Autoimmune Disease Therapy.
Read →
Is Recarbrio approved by the FDA?
Drug Insights
3 min read
Is Recarbrio approved by the FDA?
21 June 2024
The U.S. Food and Drug Administration (FDA) approved Recarbrio, which is a combination of imipenem, cilastatin, and relebactam, on July 16, 2019.
Read →
FDA Approves Zymeworks' ZW171, a New Bispecific Antibody for Mesothelin-related Tumors
Latest Hotspot
3 min read
FDA Approves Zymeworks' ZW171, a New Bispecific Antibody for Mesothelin-related Tumors
21 June 2024
Zymeworks Receives FDA Approval for ZW171, a New Bispecific Antibody Targeting Mesothelin-related Tumors.
Read →
Is Amlodipine approved by the FDA?
Drug Insights
3 min read
Is Amlodipine approved by the FDA?
21 June 2024
The U.S. Food and Drug Administration (FDA) approved amlodipine, which is marketed under brand names such as Norvasc, Katerzia, and Norliqva, for medical use. This approval was granted on July 8, 2019.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.